Here is some other vaccine news of note for the week.
After failing a phase 2 in solid-organ transplant patients, the CMV vaccine failed in hematopoietic cell transplant recipients too.
The £20 million series A backed by GV will help Vaccitech develop an MVA-vectored universal flu vaccine currently in phase 2.
Moderna unveiled two phase 1 prophylactic vaccine programs and a new Chikungunya antibody candidate at JPM.
China's ApolloBio increased upfront payment, while also terminating its right to buy into Inovio.
Sanofi's recent loss in C. diff is a win for Pfizer and Valneva, which boast their own late-stage candidates, according to GlobalData.
Here's some other vaccine news of note for the week.
VBI Vaccines is aiming for 2019 approval filings for its hepatitis B vaccine if a head-to-head trial against GSK's entrenched Engerix-B succeeds.